H.C. Wainwright sets $16 target on Astria Therapeutics stock
H.C. Wainwright maintained a Buy rating on Astria Therapeutics stock, with a price target of $16.00. The firm's decision follows Astria's announcement of the initiation of a Phase 1a study for ...
Business Wire18d
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. “We believe STAR-0310 will be the best-in-class therapy due to efficacy, safety and tolerability, and treatment burden, and could ...
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present quality ...